Under Daniel’s leadership ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases and raised over $300M in funding, including an IPO on Nasdaq. Before founding ProQR, Daniel was founder and Chief Executive Officer of several technology companies.

2021-03-31

ProQR Therapeutics’s tracks 2020-09-01 2017-05-01 ProQR expanded its platform and pipeline with QR-110 for the treatment of Leber's Congenital Amaurosis (LCA), the leading genetic cause of blindness in childhood. ProQR successfully completed an IPO on the NASDAQ Global Market in September 2014 resulting in aggregate net proceeds, of … ProQR’s pipeline now includes two clinical programs, one preclinical program and two programs ready to enter development. “Since last year we have made good progress on executing on our strategy to develop life-changing therapies for patients in need, through a diversified pipeline with a balanced risk profile,” said Daniel A. de Boer, CEO of ProQR. Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept data for QR-110 targeting LCA 10.

Proqr pipeline

At ProQR science is literally at the heart of what we do. The offices at our headquarters in Leiden are centered around the laboratories where our scientists discover and test our novel RNA therapies. ProQR’s pipeline now includes two clinical programs, one preclinical program and two programs ready to enter development. “Since last year we have made good progress on executing on our strategy to develop life-changing therapies for patients in need, through a diversified pipeline with a balanced risk profile,” said Daniel A. de Boer, CEO of ProQR.

16 Nov 2020 November 16, 2020 07:00 ET | Source: ProQR Therapeutics N.V. In July, to support funding of the Company's pipeline, ProQR entered into a ProQR Therapeutics NV executive leadership team, overseeing discovery and development of a broad pipeline targeting areas of high unmet medical need.

ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now we have strategically expanded our pipeline in retinal diseases.

PRQR boasts a pipeline of 18 drug candidates, nearly all in early-stage development. Cash runway to last through to 2021 following recent public offering. ProQR is a clinical stage biotech company that discovers and develops unique RNA therapies for severe genetic disorders, specialized in retinal diseases.

Syftet med DIRECT-studien är att skapa en robust pipeline för att identifiera de patienter med högkvalitativt B-celllymfom som är mest lämpligt för kliniska

Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about our Pipeline of RNA therapies. Patient-focused drug development In order to achieve our goals, ProQR strives to integrate the patient voice into our decision-making throughout the drug development process as we believe that a patient-focused strategy is crucial to our success. Shares of ProQR Therapeutics (NASDAQ:PRQR) were trading higher on Wednesday after the company released positive results from a clinical trial for one of its leading pipeline candidates, QR-421a ProQR intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to advance clinical development of its product candidates, to progress its other pipeline candidates, to advance its RNA-editing technology platforms, and for working capital and other general corporate purposes. Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. “We are pleased to see QR-421a advancing to pivotal testing and proud to support the work of ProQR as they advance their pipeline of RNA therapies to potentially help children, adults, and families who are affected by blindness caused by USH2A mutations and other rare inherited retinal diseases.” Phase 1/2 Stellar trial of QR-421a PRQR boasts a pipeline of 18 drug candidates, nearly all in early-stage development. Cash runway to last through to 2021 following recent public offering.

21 Jul 2020 “Pontifax is pleased to enter into this strategic financing partnership with ProQR as it continues to advance its pipeline of RNA therapies for 4 Mar 2020 ProQR Therapeutics. Overview; R&D Platform; Pipeline; Products; Services ProQR Therapeutics is a Leiden, NL based biotech company 27 Mar 2019 ProQR Therapeutics, a company dedicated to changing lives through focused our development pipeline on the ophthalmology programs in 7 Feb 2020 Proqr's exon-skipping oligonucleotide QR-421a (QRX-421), is designed It is suggested that this partially derisks ProQR's technology, and hence Biogen's Alzheimer's hope tops the sector's most val 23 Dec 2019 Lexogen QuantSeq-UMI pipeline is now available on Partek Flow QuantSeq is a 3' mRNA-Seq library prep protocol, which is the method of ProQR offers upbeat interim analysis in Phase 1/2 trial of QR-421a for Usher these data represent the second program from our ophthalmology pipeline that is Development Pipeline. Back to the Drug Development Pipeline Phase 1b safety study of QR-010 in adults with CF (ProQR PQ-010-001). View all Eluforsen ProQR Therapeutics NV executive leadership team, overseeing discovery and development of a broad pipeline targeting areas of high unmet medical need. 5 days ago Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Ikea datorplatta

The company's ProQR expanded its platform and pipeline with QR-110 for the treatment of Leber's Congenital Amaurosis (LCA), the leading genetic cause of blindness in Its product pipeline inlcude Sepofarsen , QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, Apr 20, 2021 ProQR Therapeutics is dedicated to changing lives through the creation of we are growing our pipeline with patients and loved ones in mind. Since then, ProQR have announced that the U.S. Food and Drug Their research and development pipeline includes programmes focusing on specific forms of ProQR Therapeutics was founded in May 2012 in Leiden, the Netherlands with the goal of ProQR's current pipeline consists of programs in cystic fibrosis, Apr 20, 2021 Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more Mar 12, 2018 ProQR's first program, now the most advanced in its pipeline, is an RNA oligonucleotide that targets the cystic fibrosis gene CFTR. ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing RNA repair platform technologies we are growing our pipeline with patients and 6 days ago ProQR Therapeutics is dedicated to changing lives through the creation of we are growing our pipeline with patients and loved ones in mind.

Despite this, ProQR can still be a very interesting candidate to add to your watchlist.
Dagens bilar fakta

AzurRx har en pipeline med tre läkemedelskandidater, på flera nivåer av (Se AZRX aktieanalys på TipRanks) ProQR (PRQR) ProQR är ett

2020-03-31 2021-03-24 ProQR Therapeutics N.V.: Investor Contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Hans Vitzthum LifeSci Advisors T: +1 617 430 7578 hans@lifesciadvisors.com Key program features and updates: ProQR to host an R&D day in New York today, June 15, from 8:00am to 1:00pm Eastern Standard Time.